the aid library

LIST OPTIONS

Filter

10816

Sort by:

Direction:

Download (50)

View PDF (118)

WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Download (93)

View PDF (168)

Addressing gender inequalities in national action plans on antimicrobial resistance

World Health Organisation (WHO) (2024) C_WHO

National action plans on antimicrobial resistance (AMR) often overlook the critical intersection of gender, despite evidence that exposure and susceptibility to infection, health-seeking behaviours, as well as antimicrobial prescribing and use patterns are all influenced by gender.

Download (122)

View PDF (127)

Guidance on the use of mpox vaccines. Revised edition

Pan American Health Organisation PAHO (2024) CC

Smallpox eradication was certified in 1980. Mpox has been endemic in Central and West African countries since it was first detected in 1958 . It is a zoonosis; cases are often found close to tropical rainforests where various animals carry the orthopoxvirus that causes the disease. In endemic countr... more

Download (160)

View PDF (148)

Medicines for HIV, viral hepatitis and sexually transmitted infections in low- and middle- income countries: forecasts of global demand for 2022–2026

World Health Organization WHO (2024) C_WHO

For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries. The purpose of this rep... more

Download (112)

View PDF (102)

Flexibly funding WHO? An analysis of its donors' voluntary contributions

Obichukwu I., Kennedy J., Harmer A. BMJ Global Health (2022) CC

Since the 1970s, voluntary contributions have become an increasingly important component of WHO's budget. As voluntary contributions tend to be earmarked for donor-specified programmes and projects, there are concerns that this trend has diverted focus away from WHO's strategic priorities, made coor... more

Download (220)

View PDF (174)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Download (187)

View PDF (172)

Pediatric Oncology nursing practice in Latin America and the Carribbean

World Health Organization WHO (2023) C_WHO

This technical report has been developed within the framework of the WHO Global Initiative for Childhood Cancer. Its goal is to improve the situation of children and adolescents with cancer worldwide, giving them the best chances of survival, living a full life and, above all, enjoying quality of ... more

Download (280)

View PDF (377)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (207)

View PDF (184)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (160)

View PDF (210)

Malaria action plan for the Eastern Mediterranean Region, 2022-2030

World Health Organisation (WHO) (2023) C_WHO

This action plan is intended for senior-level decision-makers in ministries of health, malaria programme managers, entomologists, and epidemiologists working on malaria and other vectorborne diseases programmes. It is also intended for decision-makers and technical and advocacy staff at other orga... more

Download (253)

View PDF (204)

Atención psicosocial del cáncer pediátrico. Módulo 01: Evaluación psicosocial

World Health Organisation (WHO) (2023) C_WHO

Los avances en el tratamiento del cáncer pediátrico han permitido ampliar las iniciativas más allá de la curación y abarcar aspectos como la detección precoz, la continuidad del tratamiento y la reducción de su toxicidad. Todo ello ha abierto paso a una visión más integral del cuidado de lo... more

Download (168)

View PDF (184)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (194)

View PDF (328)

Burden of disease attributable to unsafe drinking-water, sanitation and hygiene: 2019 update

World Health Organisation (WHO) (2023) C_WHO

The report summarizes the estimates of the burden of disease attributable to unsafe drinking water, sanitation, and hygiene for the year 2019 for four health outcomes - diarrhoea, acute respiratory infections, soil-transmitted helminthiases, and undernutrition - which are included in the reporting o... more

Download (483)

View PDF (804)

Approaches for mobile and migrant populations in the context of malaria multi-drug resistance and malaria elimination in the Greater Mekong Subregion

World Health Organization ( WHO), Regional Oﬃce for South-East-Asia (2016) C_WHO

The emergence of multifrug-resistant malaria in the Greater Mekong Subregion (‎GMS)‎ has been identified as an emergency issue that may have catastrophic consequences on the future of malaria elimination in the GMS as well as globally. In recognition of the need for a cohesive regional response,... more

Download (374)

View PDF (302)

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines
recommended

World Health Organization (WHO) (1992) C_WHO

Provides clinical descriptions, diagnostic guidelines, and codes for all mental and behavioural disorders commonly encountered in clinical psychiatry. The book was developed from chapter V of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (... more

Download (138)

View PDF (168)

Access to controlled medicines for pain management in the WHO South-East Asia Region

World Health Organisation (WHO) (2023) C_WHO

The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to these essential medicines. Enhancing access to controll... more

Download (261)

View PDF (261)

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended

World Health Organization WHO (2022) C_WHO

Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi... more

Download (93)

View PDF (127)

Die Arbeit der WHO in der Ukraine-Krise. Zwischenbericht Februar bis Juni 2022

World Health Organization (WHO) (2022) C_WHO

Der Krieg der Russischen Föderation gegen die Ukraine hat Leid und Verwüstung in einem in der Europäischen Region der WHO seit Jahrzehnten nicht gekannten Ausmaß verursacht. In der Ukraine spielt sich eine sich rasch entwickelnde humanitäre und Flüchtlingskrise ab, deren geopolitische und wirt... more

Download (346)

View PDF (320)

Module: Essential care and practice

World Health Organization WHO (2015) C_WHO

Overview Learning objectives • Name the general principles of essential care and practice. • Name management principles of priority MNS conditions. • Use effective communication skills in interactions with people with MNS conditions. • Perform assessments for priority MNS conditions. �... more

Download (181)

View PDF (331)

Global burden of mental disorders among children aged 5–14 years

M. L. Baranne; B. Falissard Child and Adolescent Psychiatry and Mental Health (2018) CC

The global burden of disease (GBD) study provides information about fatal and non-fatal health outcomes around the world. The objective of this work is to describe the burden of mental disorders among children aged 5–14 years in each of the six regions of the World Health Organisation. Data come ... more

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief recommended

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines
recommended

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Policy brief
recommended